Garbarino María Cecilia, Manzano Natalia, Messina Osvaldo, Zylberman Marcelo
Departamento de Medicina Interna, Hospital General de Agudos «Dr. Cosme Argerich», Buenos Aires, Argentina; Sección Reumatología, Hospital General de Agudos «Dr. Cosme Argerich», Buenos Aires, Argentina.
Departamento de Medicina Interna, Instituto Alexander Fleming, Buenos Aires, Argentina.
Reumatol Clin (Engl Ed). 2023 Apr;19(4):215-222. doi: 10.1016/j.reumae.2023.03.001. Epub 2023 Mar 31.
The first experiences with a group of drugs called immune checkpoint inhibitors for the treatment of cancer were described in 2010. They are currently used in many tumours, with successful survival outcomes but a new profile of adverse events. This new spectrum of immune-mediated toxicities includes an exaggerated inflammatory response of T lymphocyte and the development of autoimmune diseases or similar pathologies. Of these, of particular note are the rheumatological toxicities. This review aims to alert internists and rheumatologists to their recognition and clinical management.
2010年首次报道了一组名为免疫检查点抑制剂的药物用于治疗癌症的情况。它们目前被用于多种肿瘤，能带来成功的生存结果，但也出现了新的不良事件特征。这种新的免疫介导毒性谱包括T淋巴细胞过度的炎症反应以及自身免疫性疾病或类似病症的发生。其中，特别值得注意的是风湿性毒性。本综述旨在提醒内科医生和风湿病学家对其进行识别和临床管理。
